3.90
0.08 (2.09%)
| Penutupan Terdahulu | 3.82 |
| Buka | 3.84 |
| Jumlah Dagangan | 2,881,274 |
| Purata Dagangan (3B) | 8,178,046 |
| Modal Pasaran | 1,162,094,464 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.14 |
| Harga / Jualan (P/S) | 222.44 |
| Harga / Buku (P/B) | 7.25 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| Margin Operasi (TTM) | -1,685.01% |
| EPS Cair (TTM) | -0.550 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 25.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 35.04% |
| Nisbah Semasa (MRQ) | 3.53 |
| Aliran Tunai Operasi (OCF TTM) | -70.41 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.20 M |
| Pulangan Atas Aset (ROA TTM) | -44.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -278.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Precigen, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.40 |
|
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.56% |
| % Dimiliki oleh Institusi | 67.08% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Iridian Asset Management Llc/Ct | 30 Jun 2025 | 4,278,662 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 8.50 (HC Wainwright & Co., 117.95%) | Beli |
| Median | 8.25 (111.54%) | |
| Rendah | 8.00 (JMP Securities, 105.13%) | Beli |
| Purata | 8.25 (111.54%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 3.22 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Aug 2025 | 8.50 (117.95%) | Beli | 3.22 |
| 15 Aug 2025 | 8.50 (117.95%) | Beli | 2.94 | |
| JMP Securities | 19 Aug 2025 | 8.00 (105.13%) | Beli | 3.22 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KINDLER JEFFREY B | - | 3.46 | -174,360 | -596,602 |
| KIRK RANDAL J | - | 3.29 | -1,809,667 | -5,953,804 |
| SHAH RUTUL R | 3.51 | - | 2,000 | 7,020 |
| TENNANT PHIL | 3.63 | - | 6,000 | 21,780 |
| THOMASIAN HARRY JR. | 3.50 | - | 11,216 | 39,202 |
| Jumlah Keseluruhan Kuantiti Bersih | -1,964,811 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -6,482,404 | |||
| Purata Pembelian Keseluruhan ($) | 3.54 | |||
| Purata Jualan Keseluruhan ($) | 3.40 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KIRK RANDAL J | Pengarah | 30 Sep 2025 | Jual (-) | 1,809,667 | 3.29 | 5,953,804 |
| KINDLER JEFFREY B | Pengarah | 30 Sep 2025 | Jual (-) | 106,837 | 3.29 | 351,494 |
| TENNANT PHIL | Pegawai | 29 Sep 2025 | Beli (+) | 6,000 | 3.63 | 21,780 |
| KINDLER JEFFREY B | Pengarah | 29 Sep 2025 | Jual (-) | 67,523 | 3.63 | 245,108 |
| THOMASIAN HARRY JR. | Pegawai | 26 Sep 2025 | Beli (+) | 2,932 | 3.51 | 10,291 |
| SHAH RUTUL R | Pegawai | 26 Sep 2025 | Beli (+) | 2,000 | 3.51 | 7,020 |
| THOMASIAN HARRY JR. | Pegawai | 25 Sep 2025 | Beli (+) | 8,284 | 3.49 | 28,911 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Sep 2025 | Pengumuman | Precigen Announces Up to $125 Million Non-Dilutive Financing |
| 25 Aug 2025 | Pengumuman | Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright |
| 15 Aug 2025 | Pengumuman | Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |